Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld, Ningping Zhang, Qin Zhang, Fehmi Tabak, Adrian Streinu‐Cercel, Ji‐Yao Wang, Ramazan Idilman, Hendrik W. Reesink, Mircea Diculescu, Krzysztof Simon, Mihai Voiculescu, Meral Akdogan, Wlodzimierz Mazur, Jurrien G.P. Reijnders, Elke Verhey, Bettina E. Hansen, Harry L.A. Janssen, for the ARES Study Group – 28 October 2014 – Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required.